Price negotiations

Explore the landscape of Price negotiations in China’s pharmaceutical industry. Fineline Info & Tech delivers reliable data and insights on Price negotiations to help you navigate complexities with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

Biokin Scores Triple NMPA Breakthrough Therapy Designation – BL-M07D1, BL-M05D1, and Iza‑Bren Recognized Across Biliary Tract and Gastric Cancers
CompanyDrug

Biokin Scores Triple NMPA Breakthrough Therapy Designation – BL-M07D1, BL-M05D1, and Iza‑Bren Recognized Across Biliary Tract and Gastric Cancers

Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced that its three drug candidates – BL-M07D1, BL-M05D1, and izalontamab bretecan – have been granted Breakthrough Therapy Designation (BTD) by the Center…

Biokin's BL-M12D1 Wins NMPA Clinical Trial Approval – ADC Candidate to Be Evaluated as Monotherapy in Relapsed or Refractory Hematologic Malignancies

Biokin’s BL-M12D1 Wins NMPA Clinical Trial Approval – ADC Candidate to Be Evaluated as Monotherapy in Relapsed or Refractory Hematologic Malignancies

Haisco's HSK42360-Na Granted NMPA Breakthrough Therapy Designation – BRAF Paradoxical Breaker Targets High‑Grade Glioma with BRAF V600 Mutation

Haisco’s HSK42360-Na Granted NMPA Breakthrough Therapy Designation – BRAF Paradoxical Breaker Targets High‑Grade Glioma with BRAF V600 Mutation

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
Policy / Regulatory

Trump Signs Nine New MFN Drug Pricing Agreements, Expanding Pharma Deals to 26 Companies Covering 89% of Branded Market

Policy / Regulatory

NHSA Launches 2026 NRDL Adjustment with Expanded Eligibility Criteria and Revised Weight Standards

Novo Nordisk to Cut Semaglutide List Prices by 35‑50% – Wegovy, Ozempic, Rybelsus Standardized at $675/Month
CompanyDrug

Novo Nordisk to Cut Semaglutide List Prices by 35‑50% – Wegovy, Ozempic, Rybelsus Standardized at $675/Month

NHSA 2025 Drug Lists Add 114 Medical Insurance Drugs, 19 Commercial
Policy / Regulatory

NHSA 2025 Drug Lists Add 114 Medical Insurance Drugs, 19 Commercial

Eli Lilly & Novo Nordisk Reach U.S. Deal to Cut Obesity‑Drug Prices, Unlock Medicare & Medicaid Access
CompanyDrug

Eli Lilly & Novo Nordisk Reach U.S. Deal to Cut Obesity‑Drug Prices, Unlock Medicare & Medicaid Access

NHSA Concludes 2025 National Basic Medical Insurance Drug Catalogue Negotiation and Commercial Insurance Innovative Drug Price Talks
Policy / Regulatory

NHSA Concludes 2025 National Basic Medical Insurance Drug Catalogue Negotiation and Commercial Insurance Innovative Drug Price Talks

MediCare Negotiation Begins: 535 Generic Drugs Reviewed for 2025 Drug Catalogue
Policy / Regulatory

MediCare Negotiation Begins: 535 Generic Drugs Reviewed for 2025 Drug Catalogue

NHSA Completes 2025 Drug Negotiation Review; CAR‑T Therapies Clear the Hurdle
Policy / Regulatory

NHSA Completes 2025 Drug Negotiation Review; CAR‑T Therapies Clear the Hurdle

Show More